David s. hong (24 Ergebnisse)

Zustand: Poor. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. Book contains highlighter markings. In poor condition, suitable as a reading copy. Dust jacket in fair condition. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,700grams, ISBN:9781858983912.…

Soft cover. Zustand: Very Good. 1st Edition. Light edgewear. Binding still tight. All pages intact and free of marks.

Hardcover. Zustand: Near Fine. Zustand des Schutzumschlags: Very Good. 1st Edition. 292 pages. A clean and posssibly unread copy in full dust jacket. NOT ex-library or otherwise marked. One short 1/4" tear to dust jacket with no loss of material.

Hardcover. Zustand: Very Good. No Jacket. 350 p. maps, diagrs., tables. 22 cm. ; National Library: 003490109 LCCN: 59-13226 ; LC: DS557.C2; Dewey: 915.96 ; OCLC: 250765 ; yellow and grey cloth ; no dustjacket ; ex-lib, stamps, labels ; Contents : The culture and the society -- Historical setting -- Geography and population -- Ethnic groups and languages -- Religion -- Family -- SOcial organization -- Dynamics of political behavior -- Theory and structure of government -- Diffusion and control of information -- Foreign relations -- Basic features of the economy -- Organization and use of manpower -- Financial system -- Agricultural development -- Domestic and foreign trade -- Public healther and welfare -- Formal education -- Art and intellectual expression -- Values and patterns of living -- National attitudes . Book. …

Zustand: New. In English.

Zustand: New. David Bloome is Professor Emeritus, The Ohio State University.Ayanna F. Brown is Vice President for Strategic Growth &amp Partnerships and Professor, Erikson Institute, Chicago.Huili Hong .

Hardcover. Zustand: New.

Zustand: New. In English.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies.The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. Theauthors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There isa dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation.This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value.…

Taschenbuch. Zustand: Neu. Phase I Oncology Drug Development | Timothy A. Yap (u. a.) | Taschenbuch | x | Englisch | 2021 | Springer | EAN 9783030476847 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.…

Zustand: New. pp. xiv + 292 Illus.

Zustand: New. In English.

Zustand: New. In English.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Hardcover. Zustand: Brand New. 292 pages. 9.75x6.50x1.00 inches. In Stock.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies.The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. Theauthors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There isa dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation.This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value.…

Gebunden. Zustand: New. Researchers and policymakers, public policy and management researchers and environmentalists will welcome this important book which addresses the key issue of balancing the conflicting objectives of energy planning, environmental management and economic dev.

Zustand: New. 1996. Hardcover. . . . . . Books ship from the US and Ireland.

Hardcover. Zustand: Brand New. 362 pages. 9.25x6.10x1.02 inches. In Stock.

Zustand: New. David Bloome is Professor Emeritus, The Ohio State University.Ayanna F. Brown is Vice President for Strategic Growth &amp Partnerships and Professor, Erikson Institute, Chicago.Huili Hong .

Buch. Zustand: Neu. Neuware - Researchers and policymakers, public policy and management researchers and environmentalists will welcome this important book which addresses the key issue of balancing the conflicting objectives of energy planning, environmental management and economic development.

Gebunden. Zustand: New. Dr. Tengfei Liu holds a BE in automation and ME in control theory and engineering from the South China University of Technology, Guangzhou, as well as a Ph.D in engineering from the Australian National University, Acton, Canberra. He is a visiting.

Hardcover. Zustand: Sehr gut. Zustand des Schutzumschlags: Sehr gut. 1. Auflage. B4 : 424 Seiten/pages with 280 illustrations - The book sheds new light on the early years of China's opening to the West in essays by authors of international renown and presents a magnificent collection of works, many of which have never been shown before, by early exponents of Chinese modernism.…

Zustand: New. Pathfinder 2 - Kernregeln Monster 2Gefahren ohne Ende!Egal, wie oft Helden den Tag retten, es lauern stets neue Monster hinter der naechsten Ecke. In diesem Band findest du ueber 300 Monster, darunter fantastische Standardkreaturen wie Element.